Drugs from Bugs: The Anti-Inflammatory Drugs of Tomorrow

昆虫药物：明天的抗炎药物

基本信息

批准号：
8124051
负责人：
ANDREW D ROBERTSON
金额：
$ 0.84万
依托单位：
KEYSTONE SYMPOSIA
依托单位国家：
美国
项目类别：
财政年份：
2011
资助国家：
美国
起止时间：
2011-03-01 至 2011-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8124051
关键词：
Academia Address Adopted Anti-Inflammatory Agents Anti-inflammatory Asthma Basic Science Clinic Clinical Clinical Trials Collaborations Development Discipline Disease Drug usage Environmental Risk Factor Evolution Fostering Future Generations Genes Genome Grant Health Healthcare Human Human Genome Immune Immune system Immunology Incidence Industry Inflammatory Inflammatory Bowel Diseases Knowledge Laboratories Location Magic Mediating Mentors Methodology Outcome Patients Pharmaceutical Preparations Request for Proposals Research Research Personnel Scientist Staging Stream Technology Therapeutic Training Utah Viral Work career clinical practice drug development drug discovery expectation improved insight man meetings novel novel strategies novel therapeutics pathogen pressure research and development success symposium therapeutic development trend

项目摘要

DESCRIPTION (provided by applicant): This proposal requests support for a Keystone Symposia meeting entitled Drugs from Bugs: The Anti- Inflammatory Drugs of Tomorrow, organized by Padraic G. Fallon, Grant McFadden and Amanda E.I. Proudfoot Fichard, which will be held in Snowbird, Utah from April 3 - 7, 2011. A recent global trend is that fewer novel therapeutics are progressing from the pipeline to the clinic. This has prompted the drug research and development sector to adopt less conventional approaches in broadening the search for new drugs. The Keystone Symposia meeting on Drugs from Bugs: The Anti-Inflammatory Drugs of Tomorrow will examine the growing opportunities for discovery of novel drugs from pathogens, or the "drugs from bugs" approach. The genome of man is the product of the evolution of humans adapting to environmental factors, with infectious pathogens exerting potent selective pressure. Some of the major immune-mediated diseases of today are associated with genes that evolved to respond to pathogens. Novel therapeutic strategies and new drugs can be developed by both understanding how pathogens modulate and usurp the immune system, and also by identifying the functional molecules from pathogens. Indeed, a new generation of pathogen-derived immune modulating molecules is now in clinical trials. In this meeting leading experts will present the current status of the use of pathogens as a wellspring for new therapeutics. This forum will be an opportunity for industry to engage with academics for the development of novel strategies for drug discovery. This meeting will bring together cross-disciplinary scientists to exchange and share ideas, and thereby foster collaborations directed at the generation of new drug strategies for the future. Opportunities for interdisciplinary interactions will be significantly enhanced by the co-location of this meeting with the Keystone Symposia meeting on Evolving Approaches to Early-Stage Drug Discovery. PUBLIC HEALTH RELEVANCE: Advances in drug discovery technology have raised expectations that the global drug development industry will deliver "magic bullets" or "wonder drugs" for a range of diseases, in particular inflammatory disorders. In fact, fewer novel therapeutics are progressing from the pipeline to the clinic, and the lack of new treatments is a growing health concern due to the worldwide increase in the incidence of a range of many diseases, such as asthma and inflammatory bowel disease. The Keystone Symposia meeting on Drugs from Bugs: The Anti- Inflammatory Drugs of Tomorrow will examine the growing opportunities for discovery of novel drugs from pathogens, or the "drugs from bugs" approach.

描述（由申请人提供）：本提案请求支持由 Padraic G. Fallon、Grant McFadden 和 Amanda E.I. 组织的题为“昆虫药物：明天的抗炎药物”的 Keystone 研讨会。 Proudfoot Fichard，将于 2011 年 4 月 3 日至 7 日在犹他州斯诺伯德举行。最近的全球趋势是，从研发管线进入临床的新型疗法越来越少。这促使药物研发部门采用非常规方法来扩大新药的研究范围。关于昆虫药物：明天的抗炎药物的 Keystone 研讨会将探讨从病原体中发现新药物的日益增长的机会，或“昆虫药物”方法。人类基因组是人类适应环境因素进化的产物，传染性病原体施加了强大的选择压力。当今一些主要的免疫介导的疾病与进化来响应病原体的基因有关。通过了解病原体如何调节和篡夺免疫系统，以及识别病原体的功能分子，可以开发新的治疗策略和新药物。事实上，新一代病原体衍生的免疫调节分子目前正在进行临床试验。在这次会议上，领先的专家将介绍利用病原体作为新疗法的源泉的现状。该论坛将为业界与学术界合作开发新的药物发现策略提供机会。这次会议将汇集跨学科科学家，交流和分享想法，从而促进旨在制定未来新药战略的合作。本次会议与早期药物发现不断发展的方法 Keystone 研讨会同期举行，将大大增加跨学科互动的机会。公共健康相关性：药物发现技术的进步提高了人们的期望，即全球药物开发行业将为一系列疾病，特别是炎症性疾病提供“灵丹妙药”或“神奇药物”。事实上，从管道进入临床的新疗法越来越少，而且由于哮喘和炎症性肠病等一系列疾病的发病率在全球范围内增加，新疗法的缺乏成为一个日益严重的健康问题。关于昆虫药物：明天的抗炎药物的 Keystone 研讨会将探讨从病原体中发现新药物的日益增长的机会，或“昆虫药物”方法。